The Fc Fusion Protein Market is expanding as biologic therapies gain importance across autoimmune disorders, ophthalmology, oncology, rare diseases, and other therapeutic areas. Fc fusion proteins combine an Fc region with another functional protein component, helping developers improve therapeutic characteristics such as circulation time and dosing convenience. According to Market Research Future, the market was valued at USD 48.30 billion in 2025 and is projected to reach USD 87.10 billion by 2035, growing at a CAGR of 6.1% during 2026–2035.

Product engineering, growing biologic pipelines, and increasing biosimilar adoption are influencing industry development. North America currently represents the largest regional market, while Asia-Pacific is expected to register the fastest growth. Ophthalmology is also becoming an important opportunity because extended-duration VEGF-targeting therapies can reduce treatment frequency. Market Growth is expected to benefit from advances in protein engineering, improved manufacturing processes, and expanding access to biologic medicines.

FAQ: What are Fc fusion proteins?
Fc fusion proteins are engineered biologics that combine an Fc region with another functional protein or receptor component.

FAQ: What is driving the market?
Growing demand for biologic therapies, protein-engineering innovation, ophthalmology applications, and biosimilar expansion are key factors.